COVID-19 Related Research in DCEG

Interferon Treatment May Improve COVID-19 Outcomes

Study finds genetic variants in OAS1 influence severity; potential benefit of interferon treatment for COVID-19.

DCEG investigators are applying their expertise to accelerate our understanding of the range of outcomes in patients with COVID-19 and identify those at greatest risk of adverse outcomes. Collaboration and a multidisciplinary approach are the hallmarks of COVID-related research, often with local, state, or federal organizations, as well as international research groups all working together to advance discovery.

Research Studies

COVID-Mortality Tracker

A collaboration of epidemiologists and data scientists to monitor weekly U.S. trends in overall and cause-specific mortality since the onset of the pandemic. COVID-Mortality Tracker displays publicly-available provisional vital statistics data from the National Center for Vital Statistics at the Centers for Disease Control and Prevention (CDC). Explore the COVID-Mortality Tracker.

COVNET: Large-scale Genome-wide Association Study and Whole Genome Sequencing of COVID-19 Severity

A large genome-wide association study (GWAS) to identify common and rare germline genetic variants associated with susceptibility to severe or fatal COVID-19 disease. Learn more about COVNET.

Map of the United States made up of red cartoon people in different shades and sizes

Study of Excess Deaths Reveals Racial and Ethnic Disparities

Findings from a large surveillance study led by Meredith Shiels and colleagues published in October 2021 in Annals of Internal Medicine.

The COVIDcode Study

A collaboration with the National Human Genome Research Institute and the National Institute of Allergy and Infectious Diseases to learn more about the genetic and immunologic contributions to the severity of disease of COVID-19. Distinct from COVNET, COVIDcode is actively enrolling study participants, including NIH Clinical Center patients and NIH staff. Learn more about COVIDcode.

The COV2Base Study

A collaboration with the National Heart, Lung, and Blood Institute to examine the effect of SARS-CoV2 infection on patients with rare diseases (e.g., Li-Fraumeni syndrome, DICER1-syndrome), quantifying the frequency and severity and looking for conditions that increase risk of severe outcomes. Additionally, this project will work to identify gene, tissue, or sociodemographic characteristics that increase risk of severe COVID outcomes that may inform future genetic modifier studies.

SeroHub: COVID-19 Seroprevalence Studies

graph of seroprevalence data from SeroHub — The interactive tool on the SeroHub website displays seroprevalence values by calendar time for the studies in the database.

The COVID-19 Seroprevalence Studies Hub (SeroHub) was developed by epidemiologists, data scientists, data engineers and other researchers at the Centers for Disease Control and Prevention (CDC), the NCI, and the National Institute of Allergy and Infectious Diseases (NIAID), parts of the National Institutes of Health, to compare COVID-19 seroprevalence studies across the country.